{"id":"https://openalex.org/W3135540980","doi":"https://doi.org/10.1128/aac.02428-20","title":"Human Safety, Tolerability, and Pharmacokinetics of Molnupiravir, a Novel Broad-Spectrum Oral Antiviral Agent with Activity against SARS-CoV-2","display_name":"Human Safety, Tolerability, and Pharmacokinetics of Molnupiravir, a Novel Broad-Spectrum Oral Antiviral Agent with Activity against SARS-CoV-2","publication_year":2021,"publication_date":"2021-03-03","ids":{"openalex":"https://openalex.org/W3135540980","doi":"https://doi.org/10.1128/aac.02428-20","mag":"3135540980","pmid":"https://pubmed.ncbi.nlm.nih.gov/33649113","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/8092915"},"language":"en","primary_location":{"id":"doi:10.1128/aac.02428-20","doi":"https://doi.org/10.1128/aac.02428-20","is_oa":true,"landing_page_url":"https://doi.org/10.1128/aac.02428-20","pdf_url":null,"source":{"id":"https://openalex.org/S47215897","display_name":"Antimicrobial Agents and Chemotherapy","issn_l":"0066-4804","issn":["0066-4804","1070-6283","1098-6596"],"is_oa":false,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","doyens","jufo-3","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320263","host_organization_name":"American Society for Microbiology","host_organization_lineage":["https://openalex.org/P4310320263"],"host_organization_lineage_names":["American Society for Microbiology"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Antimicrobial Agents and Chemotherapy","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","doaj","pubmed"],"open_access":{"is_oa":true,"oa_status":"hybrid","oa_url":"https://doi.org/10.1128/aac.02428-20","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5078260740","display_name":"Wendy Painter","orcid":"https://orcid.org/0000-0001-6710-1277","observed_orcids":["https://orcid.org/0000-0001-6710-1277"]},"institutions":[],"countries":[],"is_corresponding":true,"raw_author_name":"Wendy P. Painter","raw_affiliation_strings":["Ridgeback Biotherapeutics LP, 3480 Main Highway, Unit 402, Miami, Florida 33133, United States","Ridgeback Biotherapeutics LP, Miami, Florida, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Ridgeback Biotherapeutics LP, 3480 Main Highway, Unit 402, Miami, Florida 33133, United States","institution_ids":[]},{"raw_affiliation_string":"Ridgeback Biotherapeutics LP, Miami, Florida, USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5034070895","display_name":"Wayne Holman","orcid":"https://orcid.org/0000-0003-2163-3707","observed_orcids":["https://orcid.org/0000-0003-2163-3707"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Wayne Holman","raw_affiliation_strings":["Ridgeback Biotherapeutics LP, 3480 Main Highway, Unit 402, Miami, Florida 33133, United States","Ridgeback Biotherapeutics LP, Miami, Florida, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Ridgeback Biotherapeutics LP, 3480 Main Highway, Unit 402, Miami, Florida 33133, United States","institution_ids":[]},{"raw_affiliation_string":"Ridgeback Biotherapeutics LP, Miami, Florida, USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5079191636","display_name":"Jim A. Bush","orcid":"https://orcid.org/0000-0002-6645-7041","observed_orcids":["https://orcid.org/0000-0002-6645-7041"]},"institutions":[{"id":"https://openalex.org/I4210166171","display_name":"Covance (United Kingdom)","ror":"https://ror.org/059vag305","country_code":"GB","type":"company","lineage":["https://openalex.org/I4210166171","https://openalex.org/I60638368"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Jim A. Bush","raw_affiliation_strings":["Covance Clinical Research Unit Limited, Springfield House, Hyde Street, Leeds LS2 9LH, United Kingdom","Covance Clinical Research Unit Limited, Leeds, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Covance Clinical Research Unit Limited, Springfield House, Hyde Street, Leeds LS2 9LH, United Kingdom","institution_ids":[]},{"raw_affiliation_string":"Covance Clinical Research Unit Limited, Leeds, United Kingdom","institution_ids":["https://openalex.org/I4210166171"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5043625267","display_name":"Firas Almazedi","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210166171","display_name":"Covance (United Kingdom)","ror":"https://ror.org/059vag305","country_code":"GB","type":"company","lineage":["https://openalex.org/I4210166171","https://openalex.org/I60638368"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Firas Almazedi","raw_affiliation_strings":["Covance Clinical Research Unit Limited, Springfield House, Hyde Street, Leeds LS2 9LH, United Kingdom","Covance Clinical Research Unit Limited, Leeds, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Covance Clinical Research Unit Limited, Springfield House, Hyde Street, Leeds LS2 9LH, United Kingdom","institution_ids":[]},{"raw_affiliation_string":"Covance Clinical Research Unit Limited, Leeds, United Kingdom","institution_ids":["https://openalex.org/I4210166171"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5059900765","display_name":"Hamzah Malik","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210166171","display_name":"Covance (United Kingdom)","ror":"https://ror.org/059vag305","country_code":"GB","type":"company","lineage":["https://openalex.org/I4210166171","https://openalex.org/I60638368"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Hamzah Malik","raw_affiliation_strings":["Covance Clinical Research Unit Limited, Springfield House, Hyde Street, Leeds LS2 9LH, United Kingdom","Covance Clinical Research Unit Limited, Leeds, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Covance Clinical Research Unit Limited, Springfield House, Hyde Street, Leeds LS2 9LH, United Kingdom","institution_ids":[]},{"raw_affiliation_string":"Covance Clinical Research Unit Limited, Leeds, United Kingdom","institution_ids":["https://openalex.org/I4210166171"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5005407252","display_name":"Nicola C. J. E. Eraut","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210166171","display_name":"Covance (United Kingdom)","ror":"https://ror.org/059vag305","country_code":"GB","type":"company","lineage":["https://openalex.org/I4210166171","https://openalex.org/I60638368"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Nicola C. J. E. Eraut","raw_affiliation_strings":["Covance Clinical Research Unit Limited, Springfield House, Hyde Street, Leeds LS2 9LH, United Kingdom","Covance Clinical Research Unit Limited, Leeds, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Covance Clinical Research Unit Limited, Springfield House, Hyde Street, Leeds LS2 9LH, United Kingdom","institution_ids":[]},{"raw_affiliation_string":"Covance Clinical Research Unit Limited, Leeds, United Kingdom","institution_ids":["https://openalex.org/I4210166171"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5000511723","display_name":"Merribeth J. Morin","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Merribeth J. Morin","raw_affiliation_strings":["Ridgeback Biotherapeutics LP, 3480 Main Highway, Unit 402, Miami, Florida 33133, United States","Ridgeback Biotherapeutics LP, Miami, Florida, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Ridgeback Biotherapeutics LP, 3480 Main Highway, Unit 402, Miami, Florida 33133, United States","institution_ids":[]},{"raw_affiliation_string":"Ridgeback Biotherapeutics LP, Miami, Florida, USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5072690937","display_name":"Laura J. Szewczyk","orcid":"https://orcid.org/0000-0003-0311-0654","observed_orcids":["https://orcid.org/0000-0003-0311-0654"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Laura J. Szewczyk","raw_affiliation_strings":["Ridgeback Biotherapeutics LP, 3480 Main Highway, Unit 402, Miami, Florida 33133, United States","Ridgeback Biotherapeutics LP, Miami, Florida, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Ridgeback Biotherapeutics LP, 3480 Main Highway, Unit 402, Miami, Florida 33133, United States","institution_ids":[]},{"raw_affiliation_string":"Ridgeback Biotherapeutics LP, Miami, Florida, USA","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5031547878","display_name":"George R. Painter","orcid":"https://orcid.org/0000-0002-9803-8095","observed_orcids":["https://orcid.org/0000-0002-9803-8095"]},"institutions":[{"id":"https://openalex.org/I150468666","display_name":"Emory University","ror":"https://ror.org/03czfpz43","country_code":"US","type":"education","lineage":["https://openalex.org/I150468666"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"George R. Painter","raw_affiliation_strings":["Department of Pharmacology and Chemical Biology, Emory University School of Medicine, 954 Gatewood Road NE, Atlanta, Georgia 30329, United States","Department of Pharmacology and Chemical Biology, Emory University School of Medicine, Atlanta, Georgia, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Pharmacology and Chemical Biology, Emory University School of Medicine, 954 Gatewood Road NE, Atlanta, Georgia 30329, United States","institution_ids":["https://openalex.org/I150468666"]},{"raw_affiliation_string":"Department of Pharmacology and Chemical Biology, Emory University School of Medicine, Atlanta, Georgia, USA","institution_ids":["https://openalex.org/I150468666"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":2,"corresponding_author_ids":["https://openalex.org/A5031547878","https://openalex.org/A5078260740"],"corresponding_institution_ids":["https://openalex.org/I150468666"],"apc_list":null,"apc_paid":null,"fwci":28.5788,"has_fulltext":false,"cited_by_count":396,"citation_normalized_percentile":{"value":0.99679875,"is_in_top_1_percent":true,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":99,"max":100},"biblio":{"volume":"65","issue":"5","first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10118","display_name":"SARS-CoV-2 and COVID-19 Research","score":0.7261000275611877,"subfield":{"id":"https://openalex.org/subfields/2725","display_name":"Infectious Diseases"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10118","display_name":"SARS-CoV-2 and COVID-19 Research","score":0.7261000275611877,"subfield":{"id":"https://openalex.org/subfields/2725","display_name":"Infectious Diseases"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10041","display_name":"COVID-19 Clinical Research Studies","score":0.219200000166893,"subfield":{"id":"https://openalex.org/subfields/2725","display_name":"Infectious Diseases"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10375","display_name":"Pharmacogenetics and Drug Metabolism","score":0.014499999582767487,"subfield":{"id":"https://openalex.org/subfields/3004","display_name":"Pharmacology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/molnupiravir","display_name":"molnupiravir","score":1.0},{"id":"https://openalex.org/keywords/n4-hydroxycytidine","display_name":"N4-hydroxycytidine","score":0.8360000252723694},{"id":"https://openalex.org/keywords/prodrugs","display_name":"prodrugs","score":0.7540000081062317},{"id":"https://openalex.org/keywords/ribonucleoside-analogs","display_name":"ribonucleoside analogs","score":0.843999981880188},{"id":"https://openalex.org/keywords/sars-cov-2","display_name":"SARS-CoV-2","score":0.8980000019073486},{"id":"https://openalex.org/keywords/covid-19-antiviral-therapy","display_name":"COVID-19 antiviral therapy","score":0.8859999775886536},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.9829999804496765},{"id":"https://openalex.org/keywords/food-effects-on-drug-absorption","display_name":"food effect on absorption","score":0.722000002861023},{"id":"https://openalex.org/keywords/tolerability","display_name":"tolerability","score":0.7360000014305115},{"id":"https://openalex.org/keywords/safety","display_name":"safety","score":0.5230000019073486},{"id":"https://openalex.org/keywords/dose-proportionality","display_name":"dose proportionality","score":0.7279999852180481},{"id":"https://openalex.org/keywords/rna-viruses","display_name":"RNA viruses","score":0.4560000002384186},{"id":"https://openalex.org/keywords/influenza","display_name":"influenza","score":0.4180000126361847},{"id":"https://openalex.org/keywords/mers-cov","display_name":"MERS-CoV","score":0.7639999985694885},{"id":"https://openalex.org/keywords/sars-cov","display_name":"SARS-CoV","score":0.9549999833106995}],"concepts":[{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.8185391426086426},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.8088326454162598},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7013336420059204},{"id":"https://openalex.org/C2778375690","wikidata":"https://www.wikidata.org/wiki/Q7814214","display_name":"Tolerability","level":3,"score":0.692429780960083},{"id":"https://openalex.org/C27081682","wikidata":"https://www.wikidata.org/wiki/Q269829","display_name":"Placebo","level":3,"score":0.5655949115753174},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.471985399723053},{"id":"https://openalex.org/C2778570526","wikidata":"https://www.wikidata.org/wiki/Q653197","display_name":"Rash","level":2,"score":0.4461984634399414},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.4337020218372345},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.35942497849464417},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.08184623718261719},{"id":"https://openalex.org/C204787440","wikidata":"https://www.wikidata.org/wiki/Q188504","display_name":"Alternative medicine","level":2,"score":0.0}],"mesh":[],"locations_count":4,"locations":[{"id":"doi:10.1128/aac.02428-20","doi":"https://doi.org/10.1128/aac.02428-20","is_oa":true,"landing_page_url":"https://doi.org/10.1128/aac.02428-20","pdf_url":null,"source":{"id":"https://openalex.org/S47215897","display_name":"Antimicrobial Agents and Chemotherapy","issn_l":"0066-4804","issn":["0066-4804","1070-6283","1098-6596"],"is_oa":false,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","doyens","jufo-3","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320263","host_organization_name":"American Society for Microbiology","host_organization_lineage":["https://openalex.org/P4310320263"],"host_organization_lineage_names":["American Society for Microbiology"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Antimicrobial Agents and Chemotherapy","raw_type":"journal-article"},{"id":"doi:10.1101/2020.12.10.20235747","doi":"https://doi.org/10.1101/2020.12.10.20235747","is_oa":true,"landing_page_url":"https://doi.org/10.1101/2020.12.10.20235747","pdf_url":"https://www.medrxiv.org/content/medrxiv/early/2020/12/14/2020.12.10.20235747.full.pdf","source":{"id":"https://openalex.org/S3005729997","display_name":"medRxiv","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core"],"host_organization":null,"host_organization_name":null,"host_organization_lineage":["https://openalex.org/P4310315909"],"host_organization_lineage_names":["Cold Spring Harbor Laboratory Press"],"type":"repository"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"medRxiv","raw_type":"posted-content"},{"id":"pmh:oai:pubmedcentral.nih.gov:8092915","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/8092915","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Antimicrob Agents Chemother","raw_type":"Text"},{"id":"pmid:33649113","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/33649113","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Antimicrobial agents and chemotherapy","raw_type":"Journal Article"}],"best_oa_location":{"id":"doi:10.1128/aac.02428-20","doi":"https://doi.org/10.1128/aac.02428-20","is_oa":true,"landing_page_url":"https://doi.org/10.1128/aac.02428-20","pdf_url":null,"source":{"id":"https://openalex.org/S47215897","display_name":"Antimicrobial Agents and Chemotherapy","issn_l":"0066-4804","issn":["0066-4804","1070-6283","1098-6596"],"is_oa":false,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","doyens","jufo-3","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320263","host_organization_name":"American Society for Microbiology","host_organization_lineage":["https://openalex.org/P4310320263"],"host_organization_lineage_names":["American Society for Microbiology"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Antimicrobial Agents and Chemotherapy","raw_type":"journal-article"},"sustainable_development_goals":[{"display_name":"Good health and well-being","score":0.9922999739646912,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[{"display_name":"Randomized Controlled Trial","id":"https://openalex.org/study-designs/randomized-controlled-trial"},{"display_name":"Clinical Trial","id":"https://openalex.org/study-designs/clinical-trial"}],"awards":[],"funders":[],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W3135540980.pdf","grobid_xml":"https://content.openalex.org/works/W3135540980.grobid-xml"},"referenced_works_count":17,"referenced_works":["https://openalex.org/W1623033053","https://openalex.org/W1978218725","https://openalex.org/W2059856355","https://openalex.org/W2141466246","https://openalex.org/W2595347511","https://openalex.org/W2972279236","https://openalex.org/W2979108578","https://openalex.org/W2981723136","https://openalex.org/W3005079553","https://openalex.org/W3014080169","https://openalex.org/W3014708904","https://openalex.org/W3024126428","https://openalex.org/W3034312608","https://openalex.org/W3037151855","https://openalex.org/W3037268105","https://openalex.org/W3110209099","https://openalex.org/W3163226127"],"related_works":["https://openalex.org/W7142681096","https://openalex.org/W4385442738","https://openalex.org/W4294307758","https://openalex.org/W3160238449","https://openalex.org/W4408956800","https://openalex.org/W4391670547","https://openalex.org/W3209183617","https://openalex.org/W4387392312","https://openalex.org/W4283590407","https://openalex.org/W4295519624"],"abstract_inverted_index":{"Molnupiravir,":[0],"EIDD-2801/MK-4482,":[1],"the":[2,5,67,116,127,156,178],"prodrug":[3],"of":[4,18,47,66,69,81,85,96,158,172,180,187,191],"active":[6],"antiviral":[7],"ribonucleoside":[8],"analog":[9],"\u00df-d-N4-hydroxycytidine":[10],"(NHC;":[11],"EIDD-1931),":[12],"has":[13],"activity":[14],"against":[15],"a":[16,78,93,101,134,148,153,240],"number":[17],"RNA":[19],"viruses":[20],"including":[21],"severe":[22,28],"acute":[23,29],"respiratory":[24,30,35],"syndrome":[25,31,36],"coronavirus":[26],"2,":[27],"coronavirus,":[32,37],"Middle":[33],"East":[34],"and":[38,40,44,90,124,137,189,208],"seasonal":[39],"pandemic":[41],"influenza":[42],"viruses.Single":[43],"multiple":[45,107,143],"doses":[46,108,112,227],"molnupiravir":[48],"were":[49,194,203,210,237],"evaluated":[50],"in":[51,60,75,133,147,155,163,215],"this":[52],"first-in-human,":[53],"phase":[54,104],"1,":[55],"randomized,":[56],"double-blind,":[57],"placebo-controlled":[58],"study":[59],"healthy":[61],"volunteers,":[62],"which":[63],"included":[64],"evaluation":[65],"effect":[68],"food":[70],"on":[71,229],"pharmacokinetics.EIDD-1931":[72],"appeared":[73],"rapidly":[74],"plasma,":[76],"with":[77,92,100],"median":[79],"time":[80,130],"maximum":[82,121,241],"observed":[83,122],"concentration":[84,123,128],"1.00":[86],"to":[87,200],"1.75":[88],"hours,":[89],"declined":[91],"geometric":[94],"half-life":[95],"approximately":[97],"1":[98],"hour,":[99],"slower":[102],"elimination":[103],"apparent":[105],"following":[106,142,185],"or":[109,220],"higher":[110,184],"single":[111],"(7.1":[113],"hours":[114],"at":[115],"highest":[117],"dose":[118,235,243],"tested).":[119],"Mean":[120],"area":[125],"under":[126],"versus":[129],"curve":[131],"increased":[132],"dose-proportional":[135],"manner,":[136],"there":[138,151,209],"was":[139,152,166,183,244],"no":[140,161,204,211],"accumulation":[141],"doses.":[144],"When":[145],"administered":[146],"fed":[149],"state,":[150],"decrease":[154,162],"rate":[157],"absorption,":[159],"but":[160],"overall":[164],"exposure.Molnupiravir":[165],"well":[167],"tolerated.":[168],"Fewer":[169],"than":[170],"half":[171],"subjects":[173],"reported":[174],"an":[175],"adverse":[176,181,192,206],"event,":[177],"incidence":[179],"events":[182,193,207],"administration":[186],"placebo,":[188],"93.3%":[190],"mild.":[195],"One":[196],"discontinued":[197,238],"early":[198],"due":[199],"rash.":[201],"There":[202],"serious":[205],"clinically":[212],"significant":[213],"findings":[214],"clinical":[216],"laboratory,":[217],"vital":[218],"signs,":[219],"electrocardiography.":[221],"Plasma":[222],"exposures":[223],"exceeded":[224],"expected":[225],"efficacious":[226],"based":[228],"scaling":[230],"from":[231],"animal":[232],"models;":[233],"therefore,":[234],"escalations":[236],"before":[239],"tolerated":[242],"reached.":[245]},"counts_by_year":[{"year":2026,"cited_by_count":15},{"year":2025,"cited_by_count":47},{"year":2024,"cited_by_count":44},{"year":2023,"cited_by_count":86},{"year":2022,"cited_by_count":146},{"year":2021,"cited_by_count":58}],"updated_date":"2026-11-07T11:25:07.637180","created_date":"2021-03-15T00:00:00"}